The Delaware Court of Chancery, in In re Clovis Oncology, Inc. Derivative Litigation, C.A. No. 2017-0222-JRS (consol.), memo. op. (Del. Ch. Oct. 1, 2019), declined to dismiss Caremark claims where plaintiffs alleged that the board knowingly ignored red flags warning of “mission critical” regulatory compliance failure.

NEW: Orrick discusses the decision in Board Oversight of Clinical Trials During the Pendency of the COVID-19 Pandemic.

K&L Gates discusses the decision in Another “Well-Pled” Caremark Claim Survives A Motion To Dismiss: Lessons From Recent Cases On Risk Management, Compliance Systems, And Fiduciary Duties.

Cahill discusses the decision in Delaware Court Denies Another Motion to Dismiss a Caremark Claim Against Directors.

Snell & Wilmer discusses the decision in Delaware Court of Chancery Permits Caremark Claim Alleging Directors’ Failure to Monitor Critical Company Business Operations.

WilmerHale discusses the decision in Another Reminder from Delaware About the Duty of Oversight.

Hunton Andrews Kurth discusses the decision in Further Developments in Delaware’s Duty of Director Oversight.